{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:11:03Z","timestamp":1793653863905,"version":"4.5.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01402-5","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T11:31:11Z","timestamp":1745148671000},"page":"1351-1369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Canadian Consensus Guidelines for the Management of Vitiligo"],"prefix":"10.1007","volume":"15","author":[{"given":"Vimal H.","family":"Prajapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Miller-Monthrope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ringuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,20]]},"reference":[{"issue":"12","key":"1402_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.autrev.2011.02.004","volume":"10","author":"M Sandoval-Cruz","year":"2011","unstructured":"Sandoval-Cruz M, Garcia-Carrasco M, Sanchez-Porras R, Mendoza-Pinto C, Jimenez-Hernandez M, Munguia-Realpozo P, et al. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10(12):762\u20135.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1402_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"6","key":"1402_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1402_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2133.2010.09828.x","volume":"163","author":"AR Thompson","year":"2010","unstructured":"Thompson AR, Clarke SA, Newell RJ, Gawkrodger DJ, Appearance Research Collaboration. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol. 2010;163(3):481\u20136.","journal-title":"Br J Dermatol"},{"key":"1402_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3389\/fimmu.2019.01303","volume":"10","author":"C Zeidler","year":"2019","unstructured":"Zeidler C, Pereira MP, Huet F, Misery L, Steinbrink K, Stander S. Pruritus in autoimmune and inflammatory dermatoses. Front Immunol. 2019;10:1303.","journal-title":"Front Immunol"},{"issue":"5","key":"1402_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, et al. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015;73(5):883\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1402_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018652","volume":"8","author":"E Teasdale","year":"2018","unstructured":"Teasdale E, Muller I, Abdullah Sani A, Thomas KS, Stuart B, Santer M. Views and experiences of seeking information and help for vitiligo: a qualitative study of written accounts. BMJ Open. 2018;8(1): e018652.","journal-title":"BMJ Open"},{"issue":"5","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/bjd\/ljad245","volume":"189","author":"IH Hamzavi","year":"2023","unstructured":"Hamzavi IH, Bibeau K, Grimes P, Harris JE, van Geel N, Parsad D, et al. Exploring the natural and treatment history of vitiligo: patient and healthcare professional perceptions from the global VALIANT study. Br J Dermatol. 2023;189(5):569\u201377.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1402_CR9","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Taieb A, Wolkerstorfer A, Passeron T, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force-part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37(11):2185\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1402_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"issue":"24","key":"1402_CR11","doi-asserted-by":"publisher","first-page":"17306","DOI":"10.3390\/ijms242417306","volume":"24","author":"J Perez-Bootello","year":"2023","unstructured":"Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: pathogenesis and new and emerging treatments. Int J Mol Sci. 2023;24(24):17306.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1402_CR12","doi-asserted-by":"publisher","first-page":"9749","DOI":"10.3390\/ijms24119749","volume":"24","author":"T Iwanowski","year":"2023","unstructured":"Iwanowski T, Kolkowski K, Nowicki RJ, Sokolowska-Wojdylo M. Etiopathogenesis and emerging methods for treatment of vitiligo. Int J Mol Sci. 2023;24(11):9749.","journal-title":"Int J Mol Sci"},{"key":"1402_CR13","unstructured":"Incyte Corporation and Innomar Strategies. Opzelura\u00ae (ruxolitinib cream). Product Monograph. Oakville: 2024."},{"key":"1402_CR14","unstructured":"Incyte Corporation. Opzelura\u00ae (ruxolitinib cream). Full Prescribing Information. Wilmington, DE: Incyte Corporation: 2024."},{"key":"1402_CR15","unstructured":"Incyte Biosciences U.K. Ltd. Opzelura\u00ae (ruxolitinib cream). Summary of Product Characteristics. Leatherhead, UK: 2023."},{"key":"1402_CR16","unstructured":"Incyte Biosciences Distribution BV. Opzelura\u00ae (ruxolitinib cream). Summary of Product Characteristics. Amsterdam, Netherlands: 2023."},{"key":"1402_CR17","unstructured":"ClinicalTrials.gov. NCT06118411. https:\/\/clinicaltrials.gov\/study\/NCT06118411. Accessed 20 Jan 2025."},{"key":"1402_CR18","unstructured":"ClinicalTrials.gov. NCT06163326. https:\/\/clinicaltrials.gov\/study\/NCT06163326. Accessed 20 Jan 2025."},{"key":"1402_CR19","unstructured":"ClinicalTrials.gov. NCT06113445. https:\/\/clinicaltrials.gov\/study\/NCT06113445. Accessed 30 Jan 2025."},{"issue":"7","key":"1402_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1468-3083.2007.01980.x","volume":"21","author":"JC Sitek","year":"2007","unstructured":"Sitek JC, Loeb M, Ronnevig JR. Narrowband UVB therapy for vitiligo: does the repigmentation last? J Eur Acad Dermatol Venereol. 2007;21(7):891\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1402_CR21","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-13.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"23","key":"1402_CR22","doi-asserted-by":"publisher","first-page":"7486","DOI":"10.3390\/jcm12237486","volume":"12","author":"V Pala","year":"2023","unstructured":"Pala V, Ribero S, Quaglino P, Mastorino L. Updates on potential therapeutic approaches for vitiligo: Janus kinase inhibitors and biologics. J Clin Med. 2023;12(23):7486.","journal-title":"J Clin Med"},{"issue":"10","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1402_CR25","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","volume":"69","author":"E Lilly","year":"2013","unstructured":"Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1402_CR26","doi-asserted-by":"publisher","first-page":"5617838","DOI":"10.1155\/2017\/5617838","volume":"2017","author":"V Vachiramon","year":"2017","unstructured":"Vachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K. Prevalence and clinical characteristics of itch in vitiligo and its clinical significance. Biomed Res Int. 2017;2017:5617838.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159\u201364.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1402_CR28","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1507\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1402_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ijd.13198","volume":"55","author":"AA Amer","year":"2016","unstructured":"Amer AA, Gao XH. Quality of life in patients with vitiligo: an analysis of the dermatology life quality index outcome over the past two decades. Int J Dermatol. 2016;55(6):608\u201314.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1402_CR30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1402_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1159\/000448656","volume":"232","author":"J Catucci Boza","year":"2016","unstructured":"Catucci Boza J, Giongo N, Machado P, Horn R, Fabbrin A, Cestari T. Quality of life impairment in children and adults with vitiligo: a cross-sectional study based on dermatology-specific and disease-specific quality of life instruments. Dermatology. 2016;232(5):619\u201325.","journal-title":"Dermatology"},{"issue":"9","key":"1402_CR32","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00403-023-02661-y","volume":"315","author":"JA Rios-Duarte","year":"2023","unstructured":"Rios-Duarte JA, Sanchez-Zapata MJ, Silverberg JI. Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study. Arch Dermatol Res. 2023;315(9):2597\u2013603.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1402_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.36849\/JDD.0423","volume":"22","author":"S Desai","year":"2023","unstructured":"Desai S, McCormick E, Sodha P, Friedman A. Shining a light on vitiligo and associated comorbidities: what is the evidence? J Drugs Dermatol. 2023;22(4):428\u201330.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1402_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1600-0749.2005.00242.x","volume":"18","author":"G Laberge","year":"2005","unstructured":"Laberge G, Mailloux CM, Gowan K, Holland P, Bennett DC, Fain PR, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005;18(4):300\u20135.","journal-title":"Pigment Cell Res"},{"key":"1402_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.actpsy.2022.103613","volume":"227","author":"EA Do Bu","year":"2022","unstructured":"Do Bu EA, Santos VMD, Lima KS, Pereira CR, Alexandre MES, Bezerra V. Neuroticism, stress, and rumination in anxiety and depression of people with vitiligo: an explanatory model. Acta Psychol (Amst). 2022;227:103613.","journal-title":"Acta Psychol (Amst)"},{"key":"1402_CR36","doi-asserted-by":"publisher","first-page":"6663646","DOI":"10.1155\/2021\/6663646","volume":"2021","author":"J Liu","year":"2021","unstructured":"Liu J, Tang R, Xiao Y, Luo M, Shi Y, Deng Q, et al. Meta-analytic review of high anxiety comorbidity among patients with vitiligo. Biomed Res Int. 2021;2021:6663646.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1402_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjd.15199","volume":"177","author":"YC Lai","year":"2017","unstructured":"Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708\u201318.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1402_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"O Osinubi","year":"2018","unstructured":"Osinubi O, Grainge MJ, Hong L, Ahmed A, Batchelor JM, Grindlay D, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863\u201378.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1402_CR39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/jdv.14739","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(8):1343\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1402_CR40","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1111\/jdv.17382","volume":"35","author":"J Nathalie","year":"2021","unstructured":"Nathalie J, Chang J, Ezzedine K, Rodrigues M. Health-related quality of life in paediatric patients with vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(11):e755\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1402_CR41","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2340\/00015555-1940","volume":"95","author":"AA Amer","year":"2015","unstructured":"Amer AA, McHepange UO, Gao XH, Hong Y, Qi R, Wu Y, et al. Hidden victims of childhood vitiligo: impact on parents\u2019 mental health and quality of life. Acta Derm Venereol. 2015;95(3):322\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1402_CR42","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel N, Speeckaert R, Taieb A, Ezzedine K, Lim HW, Pandya AG, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1402_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677\u201383.","journal-title":"Arch Dermatol"},{"issue":"5","key":"1402_CR44","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","volume":"136","author":"N van Geel","year":"2016","unstructured":"van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V, et al. Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative. J Investig Dermatol. 2016;136(5):978\u201384.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1402_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2017.11.032","volume":"78","author":"N van Geel","year":"2018","unstructured":"van Geel N, Wolkerstorfer A, Lommerts JE, Ezzedine K, Eleftheriadou V, Hamzavi I, et al. Validation study of the Vitiligo Extent Score-plus. J Am Acad Dermatol. 2018;78(5):1013\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1402_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/0378-6323.107637","volume":"79","author":"GS Krishna","year":"2013","unstructured":"Krishna GS, Ramam M, Mehta M, Sreenivas V, Sharma VK, Khandpur S. Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo. Indian J Dermatol Venereol Leprol. 2013;79(2):205\u201310.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"1402_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/JID.2015.398","volume":"136","author":"C Salzes","year":"2016","unstructured":"Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, et al. The Vitiligo Impact Patient Scale (VIPs): development and validation of a vitiligo burden assessment tool. J Investig Dermatol. 2016;136(1):52\u20138.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"1402_CR48","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bjd.14208","volume":"174","author":"JM Batchelor","year":"2016","unstructured":"Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success. Br J Dermatol. 2016;174(2):386\u201394.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1402_CR49","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/jdv.16226","volume":"34","author":"SE Uitentuis","year":"2020","unstructured":"Uitentuis SE, Heilmann MN, Verdaasdonk RM, Bae JM, Luiten RM, Wolkerstorfer A, et al. Ultraviolet photography in vitiligo: image quality, validity and reliability. J Eur Acad Dermatol Venereol. 2020;34(7):1590\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1402_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1402_CR51","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139.","journal-title":"Br J Dermatol"},{"key":"1402_CR52","doi-asserted-by":"publisher","first-page":"9948769","DOI":"10.1155\/2023\/9948769","volume":"2023","author":"GN Pathak","year":"2023","unstructured":"Pathak GN, Chandy RJ, Naini V, Feldman SR, Rao BK. Quality of life assessments utilized in vitiligo clinical trials. Dermatol Ther. 2023;2023:9948769.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1402_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pcmr.12561","volume":"30","author":"EY Gan","year":"2017","unstructured":"Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, Bohm M, et al. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2017;30(1):28\u201340.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"1402_CR54","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1755-148X.2011.00838.x","volume":"24","author":"N van Geel","year":"2011","unstructured":"van Geel N, Speeckaert R, Taieb A, Picardo M, Bohm M, Gawkrodger DJ, et al. Koebner\u2019s phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res. 2011;24(3):564\u201373.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"1402_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jocd.13459","volume":"20","author":"D Bassiouny","year":"2021","unstructured":"Bassiouny D, Hegazy R, Esmat S, Gawdat HI, Ahmed Ezzat M, Tawfik HA, et al. Cosmetic camouflage as an adjuvant to vitiligo therapies: effect on quality of life. J Cosmet Dermatol. 2021;20(1):159\u201365.","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"1402_CR56","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1111\/jocd.15882","volume":"22","author":"S Poondru","year":"2023","unstructured":"Poondru S, Kundu RV. Use of camouflage in vitiligo: a cross-sectional survey. J Cosmet Dermatol. 2023;22(12):3524\u20136.","journal-title":"J Cosmet Dermatol"},{"issue":"8","key":"1402_CR57","volume":"14","author":"RR Dutta","year":"2022","unstructured":"Dutta RR, Kumar T, Ingole N. Diet and vitiligo: the story so far. Cureus. 2022;14(8): e28516.","journal-title":"Cureus"},{"issue":"2","key":"1402_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40257-022-00752-6","volume":"24","author":"KN Cunningham","year":"2023","unstructured":"Cunningham KN, Rosmarin D. Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors. Am J Clin Dermatol. 2023;24(2):165\u201386.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1402_CR59","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/jocd.14899","volume":"21","author":"M Khalili","year":"2022","unstructured":"Khalili M, Amiri R, Mohammadi S, Iranmanesh B, Aflatoonian M. Efficacy and safety of traditional and surgical treatment modalities in segmental vitiligo: a review article. J Cosmet Dermatol. 2022;21(6):2360\u201373.","journal-title":"J Cosmet Dermatol"},{"key":"1402_CR60","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","volume":"10","author":"C Strehl","year":"2019","unstructured":"Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744.","journal-title":"Front Immunol"},{"issue":"2","key":"1402_CR61","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","volume":"56","author":"E Nicolaidou","year":"2007","unstructured":"Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56(2):274\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1402_CR62","unstructured":"Harris J, Papp K, Forman SB, Zdybski J, Pandya AG, Seneschal J et al. Relapse and maintenance of clinical response in the randomized withdrawal arm of the TRuE-V long term extension phase 3 study of ruxolitinib cream in vitiligo. Presented at American Academy of Dermatology (AAD) Annual Meeting; 2023 March 17\u201321; New Orleans, LA."},{"issue":"4","key":"1402_CR63","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"M Cavalie","year":"2015","unstructured":"Cavalie M, Ezzedine K, Fontas E, Montaudie H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Investig Dermatol. 2015;135(4):970\u20134.","journal-title":"J Investig Dermatol"},{"issue":"15","key":"1402_CR64","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"16","key":"1402_CR65","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"1402_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/jdpa.0000000000000041","volume":"19","author":"J McElroy","year":"2025","unstructured":"McElroy J, Casquejo RJ, Yu H, Torsiello J, Sangha AM, Buhs LP. Understanding the mechanism of disease of vitiligo and the impact on clinical management. J Dermatol Physician Assist. 2025;19(1):28\u201335.","journal-title":"J Dermatol Physician Assist"},{"issue":"12","key":"1402_CR67","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","volume":"142","author":"AG Pandya","year":"2022","unstructured":"Pandya AG, Harris JE, Lebwohl M, Hamzavi IH, Butler K, Kuo FI, et al. Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo. J Investig Dermatol. 2022;142(12):3352\u20135 (e4).","journal-title":"J Investig Dermatol"},{"key":"1402_CR68","unstructured":"Astellas Pharma US Inc. Protopic\u00ae (tacrolimus). Full Prescribing Information. Deerfield: 2011."},{"issue":"1","key":"1402_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13555-013-0028-8","volume":"3","author":"G Stinco","year":"2013","unstructured":"Stinco G, Trevisan G, Buligan C, Gregoraci G, De Marchi S, di Meo N, et al. Narrow band-ultraviolet B versus clobetasol propionate foam in the treatment of vitiligo: a retrospective study. Dermatol Ther (Heidelb). 2013;3(1):95\u2013105.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1402_CR70","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1346-8138.2010.01067.x","volume":"38","author":"M Udompataikul","year":"2011","unstructured":"Udompataikul M, Boonsupthip P, Siriwattanagate R. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J Dermatol. 2011;38(6):536\u201340.","journal-title":"J Dermatol"},{"issue":"1","key":"1402_CR71","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000513938","volume":"13","author":"S Berbert Ferreira","year":"2021","unstructured":"Berbert Ferreira S, Berbert Ferreira R, Neves Neto AC, Assef SMC, Scheinberg M. Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient. Case Rep Dermatol. 2021;13(1):190\u20134.","journal-title":"Case Rep Dermatol"},{"issue":"5","key":"1402_CR72","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1600-0781.2010.00540.x","volume":"26","author":"I Majid","year":"2010","unstructured":"Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed. 2010;26(5):230\u20134.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"3","key":"1402_CR73","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/09546634.2013.777381","volume":"25","author":"N Akdeniz","year":"2014","unstructured":"Akdeniz N, Yavuz IH, Gunes Bilgili S, Ozaydin Yavuz G, Calka O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo. J Dermatolog Treat. 2014;25(3):196\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1402_CR74","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1468-3083.2006.02035.x","volume":"21","author":"A Bhatnagar","year":"2007","unstructured":"Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21(5):638\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1402_CR75","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","volume":"159","author":"RM Hearn","year":"2008","unstructured":"Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008;159(4):931\u20135.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1402_CR76","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2230.2005.01837.x","volume":"30","author":"AJ Kanwar","year":"2005","unstructured":"Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol. 2005;30(4):332\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1402_CR77","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2014.12.026","volume":"72","author":"ST Tien Guan","year":"2015","unstructured":"Tien Guan ST, Theng C, Chang A. Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris. J Am Acad Dermatol. 2015;72(4):733\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1402_CR78","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/phpp.12321","volume":"33","author":"TF Mohammad","year":"2017","unstructured":"Mohammad TF, Silpa-Archa N, Griffith JL, Lim HW, Hamzavi IH. Home phototherapy in vitiligo. Photodermatol Photoimmunol Photomed. 2017;33(5):241\u201352.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"8","key":"1402_CR79","first-page":"371","volume":"103","author":"WL Scarlett","year":"2003","unstructured":"Scarlett WL. Ultraviolet radiation: sun exposure, tanning beds, and vitamin D levels. What you need to know and how to decrease the risk of skin cancer. J Am Osteopath Assoc. 2003;103(8):371\u20135.","journal-title":"J Am Osteopath Assoc"},{"issue":"4","key":"1402_CR80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2310\/7750.2013.12053","volume":"17","author":"AJ Kanwar","year":"2013","unstructured":"Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17(4):259\u201368.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1402_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15033","volume":"34","author":"H Mehta","year":"2021","unstructured":"Mehta H, Kumar S, Parsad D, Bishnoi A, Vinay K, Kumaran MS. Oral cyclosporine is effective in stabilizing active vitiligo: results of a randomized controlled trial. Dermatol Ther. 2021;34(5): e15033.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1402_CR82","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1111\/jdv.19400","volume":"37","author":"R Speeckaert","year":"2023","unstructured":"Speeckaert R, van Geel N. The real-life efficacy of methotrexate in vitiligo: a retrospective study and literature review. J Eur Acad Dermatol Venereol. 2023;37(11):2267\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1402_CR83","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/jdv.19402","volume":"37","author":"M Guyon","year":"2023","unstructured":"Guyon M, Merhi R, Andreu N, Boniface K, Seneschal J. Efficacy and safety of the combination of steroid pulse therapy with methotrexate for vitiligo: a pilot retrospective case series. J Eur Acad Dermatol Venereol. 2023;37(11):2264\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1402_CR84","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00403-010-1034-7","volume":"302","author":"L Khodadadi","year":"2010","unstructured":"Khodadadi L, Shafieyan S, Sotoudeh M, Dizaj AV, Shahverdi A, Aghdami N, et al. Intraepidermal injection of dissociated epidermal cell suspension improves vitiligo. Arch Dermatol Res. 2010;302(8):593\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1402_CR85","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1468-3083.2007.02407.x","volume":"22","author":"A Hartmann","year":"2008","unstructured":"Hartmann A, Broecker EB, Hamm H. Repigmentation of skin and hairs in stable vitiligo by transplantation of autologous melanocytes in fibrin suspension. J Eur Acad Dermatol Venereol. 2008;22(5):624\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1402_CR86","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/bjd.12007","volume":"167","author":"A Budania","year":"2012","unstructured":"Budania A, Parsad D, Kanwar AJ, Dogra S. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study. Br J Dermatol. 2012;167(6):1295\u2013301.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1402_CR87","first-page":"15","volume":"10","author":"AB Dillon","year":"2017","unstructured":"Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in vitiligo: an update on medical and surgical treatments. J Clin Aesthet Dermatol. 2017;10(1):15\u201328.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"1402_CR88","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/jid.2011.16","volume":"131","author":"JG van den Boorn","year":"2011","unstructured":"van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Investig Dermatol. 2011;131(6):1240\u201351.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"1402_CR89","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jdv.12762","volume":"29","author":"N van Geel","year":"2015","unstructured":"van Geel N, Depaepe L, Speeckaert R. Laser (755 nm) and cryotherapy as depigmentation treatments for vitiligo: a comparative study. J Eur Acad Dermatol Venereol. 2015;29(6):1121\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1402_CR90","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0974-2077.112670","volume":"6","author":"I Majid","year":"2013","unstructured":"Majid I, Imran S. Depigmentation therapy with Q-switched Nd: YAG laser in universal vitiligo. J Cutan Aesthet Surg. 2013;6(2):93\u20136.","journal-title":"J Cutan Aesthet Surg"},{"issue":"3","key":"1402_CR91","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4103\/ijdvl.IJDVL_409_18","volume":"86","author":"N Taneja","year":"2020","unstructured":"Taneja N, Sreenivas V, Sahni K, Gupta V, Ramam M. A cross-sectional study of spontaneous repigmentation in vitiligo. Indian J Dermatol Venereol Leprol. 2020;86(3):240\u201350.","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01402-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T18:02:27Z","timestamp":1747764147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01402-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,20]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vimal H. Prajapati has served as an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, Concert, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte Corporation, JAMP Pharma, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant; served as an investigator for AbbVie, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte Corporation, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, and UCB; and received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Harvey Lui has served as an advisor, consultant, investigator, and\/or speaker for AbbVie, Incyte Corporation, L\u2019Or\u00e9al, Novartis, and Vita Imaging. Yvette Miller-Monthrope has served as an advisor, consultant, and\/or speaker for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Fresenius Kabi, Galderma, Incyte Corporation, Janssen, Sanofi, Sun Pharma, Novartis, and UCB. Julien Ringuet has served as an advisor, consultant, and\/or speaker for AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte Corporation, Janssen, LEO Pharma, L\u2019Or\u00e9al, NKS Health, Novartis, Organon, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB; and served as an investigator for AbbVie, Alumis, Amgen, Apogee, Aristea, Aslan, Bristol Myers Squibb, Celgene, Concert Pharmaceuticals, Correvitas, DICE Therapeutics, Incyte Corporation, Innovaderm, Janssen, Kyowa Kirin, LEO Pharma, Merck, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. Irina Turchin has served as a speaker, advisor, consultant, or investigator for AbbVie, Amgen, Arcutis, Aristea, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kiniksa, LEO Pharma, Mallinckrodt, MoonLake, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and Ventyx Biosciences. H. Chih-ho Hong has served as a speaker, advisor, consultant, and\/or investigator for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Galderma, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Roche, and UCB. Charles Lynde has served as a speaker and\/or consultant for AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Eli Lilly, Fresnius Kabi, Galderma, GlaxoSmithKline, Incyte Corporation, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Or\u00e9al, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health; and has served as a principal investigator for AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Galderma, GlaxoSmithKline, Incyte Corporation, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Or\u00e9al, Medexus, MedX, Merck, MoonLake, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health. Kim A. Papp has received honoraria and\/or grants as a consultant, speaker, investigator, or scientific officer from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DICE Pharmaceuticals, DICE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab. Jensen Yeung has served as a consultant, investigator, or speaker or received honoraria from AbbVie, Amgen, Acrutis, Apogee, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galderma, Incyte Corporation, JAMP Pharma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, and UCB. Melinda J. Gooderham has served as a principal investigator for AbbVie, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Aristea, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cara Therapeutics, Coherus Biosciences, Dermira, Eli Lilly, Galderma SA, GlaxoSmithKline, Incyte Corporation, InMagene, JAMP, Janssen, LEO Pharma, MedImmune, Meiji, MoonLake, Nektar Therapeutics, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda Pharmaceutical Company, Tarsus, UCB, Ventyx, and Vyne; a consultant for AbbVie, Amgen, Apogee, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly, Janssen, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and UCB; an advisory board member for AbbVie, Amgen, Apogee, Arena Pharmaceuticals, Asana BioSciences, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly, Galderma SA, Incyte Corporation, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Union; and a paid speaker for AbbVie, Amgen, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Eli Lilly, Galderma SA, Janssen, JAMP, LEO Pharma, L\u2019Or\u00e9al, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}